Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220008342COMBINATION TABLET WITH CHEWABLE OUTER LAYER
US 13.01.2022
Int.Class A61K 9/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
22Sustained or differential release type
24Layered or laminated unitary dosage forms
Appl.No 17239319 Applicant Vitalis LLC Inventor Joseph Habboushe

A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.

2.20220008373COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS
US 13.01.2022
Int.Class A61K 31/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
235having an aromatic ring attached to a carboxyl group
24having an amino or nitro group
245Amino benzoic acid types, e.g. procaine, novocaine
Appl.No 17372158 Applicant Mark Loveless Inventor Mark Loveless

The present invention is directed to compositions, methods for preventing, treating and/or curing respiratory infections, such as infections caused by a coronavirus.

3.20220008458TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USE
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17365695 Applicant American Regent, Inc. Inventor Gopal Anyarambhatla

Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 μg to about 4,000 μg of zinc, about 40 μg to about 400 μg of copper, from about 4 μg to about 90 μg of selenium, or from about 1 μg to about 80 μg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

4.20220008542ANTI-PROTOZOAL COMPOUNDS AND USES THEREOF
US 13.01.2022
Int.Class A61K 47/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Appl.No 17487078 Applicant AUBURN UNIVERSITY Inventor Sue H. DURAN

The present disclosure provides veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The disclosure also provides methods of treating trichomoniasis in a bovine and methods of treating a Tritrichomonas foetus infection in a bovine utilizing the veterinary formulations.

5.20220008460TREATING MALE INFERTILITY SECONDARY TO SPERM OXIDATIVE STRESS
US 13.01.2022
Int.Class A61K 33/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
30Zinc; Compounds thereof
Appl.No 17476801 Applicant Parviz Gharagozloo Inventor Parviz Gharagozloo

A profertility composition for administration to infertile men with sperm oxidative stress is disclosed. The composition comprises a unique combination of a pharmaceutically acceptable vitamin E, vitamin D, vitamin C, selenium, zinc, folate, lycopene, at least one carnitine source, and optionally Coenzyme Q10. Also disclosed are methods of treating male infertility.

6.WO/2022/006636COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA (OSA)
WO 13.01.2022
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/AU2021/050734 Applicant INCANNEX HEALTHCARE LIMITED Inventor BLEACKLEY, Mark Robert
The present disclosure relates generally to compositions comprising Δ-9-tetrahydrocannabinol (THC) and a carbonic anhydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). In a particular embodiment, the treatment method comprises administering dronabinol and acetazolamide and combinations thereof to a subject in need.
7.WO/2022/007461IMMUNOMODULATOR
WO 13.01.2022
Int.Class C07D 409/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
Appl.No PCT/CN2021/087548 Applicant HITGEN INC. Inventor LI, Jin
Disclosed is an immunomodulator, and the present invention specifically relates to a compound for inhibiting IL-17A and an application of the compound serving as the immunomodulator in the preparation of a drug. Disclosed is an application of a compound represented by formula I or a stereoisomer thereof in preparing a drug for inhibiting IL-17A, and a new choice for clinically screening and/or preparing a drug for treating diseases related to IL-17A activity is provided.
8.WO/2022/007866FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF
WO 13.01.2022
Int.Class C07D 233/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72Two oxygen atoms, e.g. hydantoin
76with substituted hydrocarbon radicals attached to the third ring carbon atom
Appl.No PCT/CN2021/105088 Applicant SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Inventor WU, Junjun
A fused tricyclic derivative relating to the technical field of chemical drugs, a preparation method therefor, and a pharmaceutical application thereof. The fused tricyclic derivative is an inhibitor of aggrecanase-2 (ADAMTS-5). Also provided are a pharmaceutical composition comprising the compound and a use of the compound in the preparation of a drug for treating diseases such as osteoarthritis.
9.WO/2022/0079863'3' CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE
WO 13.01.2022
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
Appl.No PCT/CZ2021/050043 Applicant INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V. V. I. Inventor BIRKUS, Gabriel
The present disclosure relates to 3'3' cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines. (Formula (J))
10.WO/2022/008586COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS
WO 13.01.2022
Int.Class A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
Appl.No PCT/EP2021/068800 Applicant GRIFOLS WORLDWIDE OPERATIONS LIMITED Inventor BARNETT, Thomas
Disclosed herein are pharmaceutical compositions containing transferrin and, or lactoferrin for use in promoting and or inducing the generation new neural cells in a patient that has suffered a neurodegenerative event arising from at least one of a traumatic brain injury, a non-traumatic brain injury, a spinal cord injury, a peripheral nerve injury, or peripheral neuropathy. Ideally, the transferrin and/or lactoferrin have a low iron saturation.